Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 349 clinical trials
featured
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

metastatic urothelial carcinoma
bladder cancer
bladder carcinoma
urothelial carcinoma
  • 22 views
  • 14 Dec, 2020
  • 64 locations
featured
Muscle-Invasive Bladder Cancer

People with bladder cancer are asked to participate in a research study being conducted by Northwell Health.  

  • 41 views
  • 23 Jan, 2020
  • 1 location
featured
Muscle- Invasive Bladder Cancer (MIBC)

People with bladder cancer are asked to participate in a research study being conducted by Montefiore Medical Center.

  • 35 views
  • 30 Jan, 2020
  • 1 location
featured
KEYNOTE-676 (HRNMIBC) bladder cancer

People with bladder cancer are asked to participate in a research study being conducted by Northwell Health.  

  • 31 views
  • 22 Feb, 2019
  • 1 location
featured
BCG Naïve Non-Muscle Invasive Bladder Cancer

People with bladder cancer are asked to participate in a research study being conducted by Montefiore Medical Center.  

  • 13 views
  • 09 Jan, 2020
  • 1 location
featured
A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer

A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer

  • 142 views
  • 08 Nov, 2020
  • 1 location
featured
A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)

A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)

  • 196 views
  • 08 Nov, 2020
  • 1 location
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

This is an open-label, randomized, multicentric study in patients with high-risk non-muscle invasive bladder cancer who had never received BCG for this disease. The objective is to

neutrophil count
invasive bladder cancer
gilbert's syndrome
bladder cancer
carcinoma
  • 0 views
  • 24 Jan, 2021
  • 25 locations
A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors

This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA). The study is comprised of two groups; dose optimization and dose expansion cohorts. Dose Optimization will include first-line and second-line melanoma, non-small cell lung cancer (NSCLC), urothelial …

metastatic urothelial carcinoma
BRAF
epidermal growth factor receptor
nktr-214
pd-l1
  • 1682 views
  • 17 Jan, 2021
  • 66 locations
Atezolizumab and BCG in High Risk BCG na ve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

Patients with high-risk non-muscle invasive bladder cancer (NMIBC) are usually managed by transurethral resection of their bladder tumor (TURBT) alone plus additional intravesical therapy to

bladder cancer
tumor cells
carcinoma
carcinoma of the bladder
carcinoma in situ
  • 0 views
  • 04 Nov, 2020